Robert Williamson

The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.

EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California.

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Strategic Enzyme Applications, Inc. engaged in organic chemical manufacturer company. The company was headquartered in San Diego, CA.

Sidecar Therapeutics, Inc. operates as a biotechnology and pharmaceutical company. It focuses on drug development for fibrotic disease. The company was founded in 2016 and is headquartered in San Diego, CA.

Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ.

ATXCo, Inc. develops clinical programs for the inhibition of fibrotic diseases. Its core asset is PAT-409, a Phase I ready autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF), NASH (nonalcoholic steatohepatitis), PBC (primary biliary cholangitis), scleroderma and chronic kidney disease. The company is headquartered in San Diego, CA.

Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL.

HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation.

Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018.